The successful close of Akribion's seed financing round is a significant milestone that represents a huge step in Akribion's mission to develop a platform of novel therapeutics that are based on their proprietary G-dase® E nucleases.

This groundbreaking family of nucleases deliver highly specific, programmable cell depletion via RNA biomarker recognition. A transformational technology that the Akribion team intend to first apply in oncology, but that should also bear huge potential for other application fields. The G-dase® E technology has been exclusively licensed for all therapeutic applications from BRAIN Biotech AG.

This seed funding round will help Akribion to achieve key development milestones and extend the team and platform that will be able to execute on the huge potential of their technology.

Read more here.